3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
1
Status
Terminated
2
Completed
2
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Other hematologic neoplasm
4
Myeloid
4
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
50
Leukemia
15
Gastrointestinal Stromal Tumors
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia, Myeloid, Chronic-Phase
8
Neoplasms
5
Philadelphia Chromosome
4
Myeloproliferative Disorders
4
Leukemia, Myeloid
4
Bone Marrow Diseases
4
Blast Crisis
4
Hematologic Diseases
3
Hematologic Neoplasms
2
Bronchiolitis Obliterans Syndrome
2
Recurrence
1
Piebaldism
1
Neoplastic Processes
1
Neoplasms by Histologic Type
1
Melanoma
1
Mastocytosis, Systemic
1
Leukemia, Myeloid, Accelerated Phase
1
Hypereosinophilic Syndrome
1
Disease Progression
1
Interventions
Imatinib Mesylate
5
ruxolitinib
4
ponatinib
4
nilotinib
4
Azacitidine
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
spartalizumab
1
sonidegib
1
simtuzumab
1
sabatolimab
1
bosutinib
1
Zoledronic Acid
1
SCIO-469
1
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
1
Denosumab
1
Decitabine
1
CPI-0610
1
BID protein, human
1
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
INDUSTRY
×
Bone Marrow Diseases
×
nilotinib
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA
NCT00471497
2020-11-18
ENESTnd
Novartis
Phase 3
Completed
846 enrolled
33 charts
NCT00519090
2011-11-07
ENEST
Novartis
Phase 3
Terminated
6 enrolled
6 charts